IL6 and congenital rubella syndrome: The dramatic need of treatment options for SARS-CoV-2 infection, the instrumental role played by IL-6 in the pathogenesis of COVID-19-associated CRS, and the well-known safety profile of the agent [18, 19] prompted the off-label use of TCZ early in the course of the pandemic.